The expression of Nectin-4 on the surface of ovarian cancer cells alters their ability to adhere, migrate, aggregate, and proliferate

Oncotarget

Volumn 8, Issue 6, 2017, Pages 9717-9738

  Boylan, Kristin L M ^a   Buchanan, Petra C ^a   Manion, Rory D ^a   Shukla, Dip M ^a   Braumberger, Kelly ^a   Bruggemeyer, Cody ^a   Skubitz, Amy P N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Cell adhesion; Migration; Nectin 4; Ovarian cancer; Spheroids

Indexed keywords

CELL ADHESION MOLECULE; NECTIN 1; NECTIN 4; UNCLASSIFIED DRUG; NECTIN; NECTIN1 PROTEIN, HUMAN; NECTIN4 PROTEIN, HUMAN; PROTEIN BINDING;

ARTICLE; ASCITES CELL; CANCER GROWTH; CELL ADHESION; CELL AGGREGATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; METASTASIS; OVARIAN CANCER CELL LINE; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; TIME; TUMOR SPHEROID; CELL MEMBRANE; CELL MOTION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE; TUMOR INVASION;

CELL ADHESION; CELL ADHESION MOLECULES; CELL AGGREGATION; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NECTINS; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PROTEIN BINDING; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 85012010007     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.14206     Document Type: Article

References (68)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians. 2015; 65:5-29.
2. Romero I, Bast RC, Jr. Minireview: Human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 2012; 153:1593-1602.
3. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, BischoffFZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014; 26:77-91.
4. Perets R, Drapkin R. It's Totally Tubular. Riding The New Wave of Ovarian Cancer Research. Cancer Research. 2016; 76:10-17.
5. Yoshida Y, Kurokawa T, Nishikawa Y, Orisa M, Kleinman HK, Kotsuji F. Laminin-1-derived scrambled peptide AG73T disaggregates laminin-1-induced ovarian cancer cell spheroids and improves the efficacy of cisplatin. International Journal of Oncology. 2008; 32:673-681.
6. Desoize B, Jardillier J. Multicellular resistance: A paradigm for clinical resistance? Critical Reviews in Oncology/Hematology. 2000; 36:193-207.
7. Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR, Jr., Skubitz AP. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecologic Oncology. 2004; 93:170-181.
8. Burleson KM, Hansen LK, Skubitz AP. Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clinical & Experimental Metastasis. 2004; 21:685-697.
9. Casey RC, Burleson KM, Skubitz KM, Pambuccian SE, Oegema TR, Jr., RuffLE, Skubitz AP. Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. The American Journal of Pathology. 2001; 159:2071-2080.
10. Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, Ladanyi A, Penicka CV, George J, Matlin K, Montag A, Wroblewski K, Yamada SD, Mazar AP, Bowtell D, Lengyel E. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. The Journal of Clinical Investigation. 2014; 124:4614-4628.
11. Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MS. Epithelial ovarian cancer experimental models. Oncogene. 2014; 33:3619-3633.
12. Burleson KM, Boente MP, Pambuccian SE, Skubitz AP. Disaggregation and invasion of ovarian carcinoma ascites spheroids. Journal of Translational Medicine. 2006; 4:6.
13. Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. The Journal of Clinical Investigation. 2014; 124:2611-2625.
14. Kenny HA, Dogan S, Zillhardt M, A KM, Yamada SD, Krausz T, Lengyel E. Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treatment and Research. 2009; 149:335-351.
15. Peart T, Ramos Valdes Y, Correa RJ, Fazio E, Bertrand M, McGee J, Prefontaine M, Sugimoto A, DiMattia GE, Shepherd TG. Intact LKB1 activity is required for survival of dormant ovarian cancer spheroids. Oncotarget. 2015; 6:22424-22438. doi: 10.18632/oncotarget.4211.
16. Stadlmann S, Feichtinger H, Mikuz G, Marth C, Zeimet AG, Herold M, Knabbe C, Offner FA. Interactions of human peritoneal mesothelial cells with serous ovarian cancer cell spheroids evidence for a mechanical and paracrine barrier function of the peritoneal mesothelium. International Journal of Gynecological Cancer. 2014; 24:192-200.
17. Hibbs K, Skubitz KM, Pambuccian SE, Casey RC, Burleson KM, Oegema TR, Jr., Thiele JJ, Grindle SM, Bliss RL, Skubitz AP. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. The American Journal of Pathology. 2004; 165:397-414.
18. DeRycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M, Bliss RL, Geller MA, Argenta PA, Harrington KM, Skubitz AP. Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. American Journal of Clinical Pathology. 2010; 134:835-845.
19. Nabih ES, Abdel Motaleb FI, Salama FA. The diagnostic efficacy of nectin 4 expression in ovarian cancer patients. Biomarkers. 2014; 19:498-504.
20. Brancati F, Fortugno P, Bottillo I, Lopez M, Josselin E, Boudghene-Stambouli O, Agolini E, Bernardini L, Bellacchio E, Iannicelli M, Rossi A, Dib-Lachachi A, Stuppia L, Palka G, Mundlos S, Stricker S, et al. Mutations in PVRL4, encoding cell adhesion molecule nectin-4, cause ectodermal dysplasia-syndactyly syndrome. American Journal of Human Genetics. 2010; 87:265-273.
21. Reymond N, Fabre S, Lecocq E, Adelaide J, Dubreuil P, Lopez M. Nectin4/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interaction. The Journal of Biological Chemistry. 2001; 276:43205-43215.
22. Nishiwada S, Sho M, Yasuda S, Shimada K, Yamato I, Akahori T, Kinoshita S, Nagai M, Konishi N, Nakajima Y. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. Journal of Experimental & Clinical Cancer Research. 2015; 34:30.
23. Lattanzio R, Ghasemi R, Brancati F, Sorda RL, Tinari N, Perracchio L, Iacobelli S, Mottolese M, Natali PG, Piantelli M. Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer. Oncogenesis. 2014; 3:e118.
24. Fabre-Lafay S, Monville F, Garrido-Urbani S, Berruyer-Pouyet C, Ginestier C, Reymond N, Finetti P, Sauvan R, Adelaide J, Geneix J, Lecocq E, Popovici C, Dubreuil P, Viens P, Goncalves A, Charafe-Jauffret E, et al. Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer. 2007; 7:73.
25. Fabre-Lafay S, Garrido-Urbani S, Reymond N, Goncalves A, Dubreuil P, Lopez M. Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factoralpha-converting enzyme (TACE)/ADAM-17. The Journal of Biological Chemistry. 2005; 280:19543-19550.
26. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K, Nishimura H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Research. 2009; 69:6694-6703.
27. Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, Capo L, Verlinsky A, Leavitt M, Malik F, Avina H, Guevara CI, et al. Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 Is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Research. 2016; 76:3003-3013.
28. Agensys I. (2014). A Phase 1 study of the safety and pharmacokinetics of escalating doses of ASG-22CE given as monotherapy in subjects with metastatic urothelial cancer and other malignant solid tumors that express Nectin-4. (ClinicalTrials.gov.)
29. Takai Y, Nakanishi H. Nectin and afadin: novel organizers of intercellular junctions. Journal of Cell Science. 2003; 116:17-27.
30. Kurita S, Ogita H, Takai Y. Cooperative role of nectinnectin and nectin-afadin interactions in formation of nectin-based cell-cell adhesion. The Journal of Biological Chemistry. 2011; 286:36297-36303.
31. Yamada A, Fujita N, Sato T, Okamoto R, Ooshio T, Hirota T, Morimoto K, Irie K, Takai Y. Requirement of nectin, but not cadherin, for formation of claudin-based tight junctions in annexin II-knockdown MDCK cells. Oncogene. 2006; 25:5085-5102.
32. Fukuhara A, Irie K, Yamada A, Katata T, Honda T, Shimizu K, Nakanishi H, Takai Y. Role of nectin in organization of tight junctions in epithelial cells. Genes to Cells. 2002; 7:1059-1072.
33. Honda T, Shimizu K, Fukuhara A, Irie K, Takai Y. Regulation by nectin of the velocity of the formation of adherens junctions and tight junctions. Biochemical and Biophysical Research Communications. 2003; 306:104-109.
34. Takahashi K, Nakanishi H, Miyahara M, Mandai K, Satoh K, Satoh A, Nishioka H, Aoki J, Nomoto A, Mizoguchi A, Takai Y. Nectin/PRR: an immunoglobulin-like cell adhesion molecule recruited to cadherin-based adherens junctions through interaction with Afadin, a PDZ domain-containing protein. The Journal of Cell Biology. 1999; 145:539-549.
35. Sakisaka T, Takai Y. Biology and pathology of nectins and nectin-like molecules. Current Opinion in Cell Biology. 2004; 16:513-521.
36. Yasumi M, Shimizu K, Honda T, Takeuchi M, Takai Y. Role of each immunoglobulin-like loop of nectin for its cell-cell adhesion activity. Biochemical and Biophysical Research Communications. 2003; 302:61-66.
37. Kim DY, Ingano LA, Kovacs DM. Nectin-1alpha, an immunoglobulin-like receptor involved in the formation of synapses, is a substrate for presenilin/gamma-secretaselike cleavage. The Journal of Biological Chemistry. 2002; 277:49976-49981.
38. Kim J, Lilliehook C, Dudak A, Prox J, Saftig P, FederoffHJ, Lim ST. Activity-dependent alpha-cleavage of nectin-1 is mediated by a disintegrin and metalloprotease 10 (ADAM10). The Journal of Biological Chemistry. 2010; 285:22919-22926.
39. Lim ST, Chang A, Giuliano RE, FederoffHJ. Ectodomain shedding of nectin-1 regulates the maintenance of dendritic spine density. Journal of Neurochemistry. 2012; 120:741-751.
40. Fabre S, Reymond N, Cocchi F, Menotti L, Dubreuil P, Campadelli-Fiume G, Lopez M. Prominent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin 4 bind to the predicted C-C'-C"-D beta-strands of the nectin1 V domain. The Journal of Biological Chemistry. 2002; 277:27006-27013.
41. Irie K, Shimizu K, Sakisaka T, Ikeda W, Takai Y. Roles and modes of action of nectins in cell-cell adhesion. Seminars in Cell & Developmental Biology. 2004; 15:643-656.
42. Amano H, Ikeda W, Kawano S, Kajita M, Tamaru Y, Inoue N, Minami Y, Yamada A, Takai Y. Interaction and localization of Necl-5 and PDGF receptor beta at the leading edges of moving NIH3T3 cells: Implications for directional cell movement. Genes to Cells. 2008; 13:269-284.
43. Bojesen KB, Clausen O, Rohde K, Christensen C, Zhang L, Li S, Kohler L, Nielbo S, Nielsen J, Gjorlund MD, Poulsen FM, Bock E, Berezin V. Nectin-1 binds and signals through the fibroblast growth factor receptor. The Journal of Biological Chemistry. 2012; 287:37420-37433.
44. Kajita M, Ikeda W, Tamaru Y, Takai Y. Regulation of platelet-derived growth factor-induced Ras signaling by poliovirus receptor Necl-5 and negative growth regulator Sprouty2. Genes to Cells. 2007; 12:345-357.
45. Kanzaki N, Ogita H, Komura H, Ozaki M, Sakamoto Y, Majima T, Ijuin T, Takenawa T, Takai Y. Involvement of the nectin-afadin complex in PDGF-induced cell survival. Journal of Cell Science. 2008; 121:2008-2017.
46. Kinugasa M, Amano H, Satomi-Kobayashi S, Nakayama K, Miyata M, Kubo Y, Nagamatsu Y, Kurogane Y, Kureha F, Yamana S, Hirata K, Miyoshi J, Takai Y, Rikitake Y. Necl-5/poliovirus receptor interacts with VEGFR2 and regulates VEGF-induced angiogenesis. Circulation Research. 2012; 110:716-726.
47. Minami A, Mizutani K, Waseda M, Kajita M, Miyata M, Ikeda W, Takai Y. Necl-5/PVR enhances PDGF-induced attraction of growing microtubules to the plasma membrane of the leading edge of moving NIH3T3 cells. Genes to Cells. 2010; 15:1123-1135.
48. Ogita H, Takai Y. Cross-talk among integrin, cadherin, and growth factor receptor: roles of nectin and nectinlike molecule. International Review of Cytology. 2008; 265:1-54.
49. Sakisaka T, Ikeda W, Ogita H, Fujita N, Takai Y. The roles of nectins in cell adhesions: cooperation with other cell adhesion molecules and growth factor receptors. Current Opinion in Cell Biology. 2007; 19:593-602.
50. Pavlova NN, Pallasch C, Elia AE, Braun CJ, Westbrook TF, Hemann M, Elledge SJ. A role for PVRL4-driven cell-cell interactions in tumorigenesis. eLife. 2013; 2:e00358.
51. Takai Y, Irie K, Shimizu K, Sakisaka T, Ikeda W. Nectins and nectin-like molecules: roles in cell adhesion, migration, and polarization. Cancer Science. 2003; 94:655-667.
52. Nakanishi H, Takai Y. Roles of nectins in cell adhesion, migration and polarization. Biological Chemistry. 2004; 385:885-892.
53. Ogita H, Ikeda W, Takai Y. Roles of cell adhesion molecules nectin and nectin-like molecule-5 in the regulation of cell movement and proliferation. Journal of Microscopy. 2008; 231:455-465.
54. Tomasz M, Lipman R, Chowdary D, Pawlak J, Verdine GL, Nakanishi K. Isolation and structure of a covalent crosslink adduct between mitomycin C and DNA. Science. 1987; 235:1204-1208.
55. Satoh-Horikawa K, Nakanishi H, Takahashi K, Miyahara M, Nishimura M, Tachibana K, Mizoguchi A, Takai Y. Nectin-3, a new member of immunoglobulin-like cell adhesion molecules that shows homophilic and heterophilic cell-cell adhesion activities. The Journal of Biological Chemistry. 2000; 275:10291-10299.
56. Harrison OJ, Vendome J, Brasch J, Jin X, Hong S, Katsamba PS, Ahlsen G, Troyanovsky RB, Troyanovsky SM, Honig B, Shapiro L. Nectin ectodomain structures reveal a canonical adhesive interface. Nature Structural & Molecular Biology. 2012; 19:906-915.
57. Boylan KL, Misemer B, Derycke MS, Andersen JD, Harrington KM, Kalloger SE, Gilks CB, Pambuccian SE, Skubitz AP. Claudin 4 Is Differentially Expressed between Ovarian Cancer Subtypes and Plays a Role in Spheroid Formation. International Journal of Molecular Sciences. 2011; 12:1334-1358.
58. Yin B, Li KH, An T, Chen T, Peng XZ. Nectin-like molecule 1 inhibits the migration and invasion of U251 glioma cells by regulating the expression of an extracellular matrix protein osteopontin. Chinese Medical Sciences Journal. 2010; 25:100-104.
59. Wang C, Chowdhury S, Driscoll M, Parent CA, Gupta SK, Losert W. The interplay of cell-cell and cell-substrate adhesion in collective cell migration. Journal of the Royal Society. 2014; 11:20140684.
60. Sodek KL, Ringuette MJ, Brown TJ. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. International journal of cancer. 2009; 124:2060-2070.
61. Buchanan PC, Boylan KLM, Walcheck B, Heinze R, Geller MA, Argenta PA, Skubitz APN. Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17. Journal of Biological Chemistry. 2016; submitted.
62. Liu Y, Burkhalter R, Symowicz J, Chaffin K, Ellerbroek S, Stack MS. Lysophosphatidic acid disrupts junctional integrity and epithelial cohesion in ovarian cancer cells. Journal of Oncology. 2012; 2012:501492.
63. Prelich G. Gene overexpression: uses, mechanisms, and interpretation. Genetics. 2012; 190:841-854.
64. Zhou B, Moodie A, Blanchard AA, Leygue E, Myal Y. Claudin 1 in breast cancer: New insights. Journal of Clinical Medicine. 2015; 4:1960-1976.
65. Kleinberg L, Holth A, Trope CG, Reich R, Davidson B. Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Human Pathology. 2008; 39:747-757.
66. Suh Y, Yoon CH, Kim RK, Lim EJ, Oh YS, Hwang SG, An S, Yoon G, Gye MC, Yi JM, Kim MJ, Lee SJ. Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene. 2013; 32:4873-4882.
67. Hamilton TC, Young RC, Ozols RF. Experimental model systems of ovarian cancer: Applications to the design and evaluation of new treatment approaches. Seminars in Oncology. 1984; 11:285-298.
68. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nature Methods. 2012; 9:671-675.